| 28.235 -0.005 (-0.02%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 34.09 | 1-year : | 39.82 |
| Resists | First : | 29.19 | Second : | 34.09 |
| Pivot price | 27.66 |
|||
| Supports | First : | 25.6  |
Second : | 23.38 |
| MAs | MA(5) : | 28.17 |
MA(20) : | 27.41 |
| MA(100) : | 30.51 |
MA(250) : | 0 | |
| MACD | MACD : | 0.3 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 71.7 |
D(3) : | 72.6 |
| RSI | RSI(14): 56.6 |
|||
| 52-week | High : | 42.5 | Low : | 22.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CAI ] has closed below upper band by 29.6%. Bollinger Bands are 57.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 28.38 - 28.52 | 28.52 - 28.64 |
| Low: | 27.53 - 27.68 | 27.68 - 27.81 |
| Close: | 28.01 - 28.25 | 28.25 - 28.45 |
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
Wed, 24 Dec 2025
Caris Life Sciences: Stronger Fundamentals, Same Conclusion (CAI) - Seeking Alpha
Mon, 22 Dec 2025
Canaccord Genuity Maintains Caris Life Sciences (CAI) Hold Recommendation - Nasdaq
Wed, 17 Dec 2025
Caris Life Sciences (CAI): Rethinking Valuation After a Recent Share Price Rebound - Yahoo Finance
Fri, 12 Dec 2025
Power Luke Thomas sells Caris Life Sciences (CAI) stock for $1.65m - Investing.com
Mon, 08 Dec 2025
Can Caris Life Sciences,?Inc. (CAI) Climb 32.81% to Reach the Level Wall Street Analysts Expect? - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 282 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 48.4 (%) |
| Held by Institutions | 47.6 (%) |
| Shares Short | 6,840 (K) |
| Shares Short P.Month | 4,190 (K) |
| EPS | -3.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.7 |
| Profit Margin | -28.9 % |
| Operating Margin | 15 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 113.4 % |
| Gross Profit (p.s.) | 1.38 |
| Sales Per Share | 2.3 |
| EBITDA (p.s.) | -0.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -8.03 |
| PEG Ratio | 0 |
| Price to Book value | 16.6 |
| Price to Sales | 12.27 |
| Price to Cash Flow | -14590.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|